title: Case studies of kyphoplasty and vertebroplasty integrated by anti-osteoporotic therapy.
abstract: In severe osteoporosis with recent vertebral compression fracture, drug treatment with anabolic agent in the first 18 months can stimulate the healing process and reduce the rate of progression, preventing new fractures and improving the quality of life of the patient. The sequential therapy with bisphosphonates for at least another 12 months can help to maintain balanced bone turnover markers without the incidence of new fractures. The association of kyphoplasty or vertebroplasty and anti-osteoporotic drugs can be limited by national rules of eligibility. Hence the need for shared treatment protocols.
authors.affiliation: Orthopaedic and Traumatologic Clinic, University of Milan c/o Ist Orthopaedic and Traumatologic Division, AO Orthopaedic Institute "Gaetano Pini", Milan, Italy. costantino.corradini@unimi.it
authors.forename: Costantino
authors.initials: C
authors.lastname: Corradini
authors.forename: Emiliano
authors.initials: E
authors.lastname: Malagoli
authors.forename: Cesare
authors.initials: C
authors.lastname: Verdoia
mesh_terms: D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D006801:Humans; D007558:Italy; D058498:Kyphoplasty / Q000379:methods*; D009985:Orthopedics / Q000379:methods* / Q000592:standards; D010024:Osteoporosis / Q000188:drug therapy; D019904:Polymethyl Methacrylate / Q000627:therapeutic use; D011788:Quality of Life; D012107:Research Design; D019379:Teriparatide / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D054854:Vertebroplasty / Q000379:methods*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide; D019904:Polymethyl Methacrylate